ArticleBlood2018
Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 62 citations in OpenAlex.
- Early anti-coagulation therapy in new-onset atrial fibrillation after coronary artery bypass grafting: a randomized trial pilot study.BMC cardiovascular disorders · 2024Trial
- Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.Scientific reports · 2019Trial
- Warfarin-Induced Developmental Toxicity: Insights into Embryogenesis, Teratogenicity, and Molecular Pathways.Journal of developmental biology · 2026Review
- Sex-Related Effect of Chronic Doses of Warfarin and Menadione onInternational journal of molecular sciences · 2026Article
- Contained Juxtarenal Aortic Perforation in the Setting of Severe Warfarin-Associated Coagulopathy.JACC. Case reports · 2026Article
- Identification of PRRG1 as a possible molecular target of pancreatic cancer.Cell death & disease · 2026Article
- Identification of berbamine hydrochloride as a novel coagulation factor VII inhibitor by natural product library screening using zebrafish as a model.Scientific reports · 2026Article
- Deep vein thrombosis incidence after sequential Low-molecular-weight heparin and Rivaroxaban versus no prophylaxis in posterior cruciate ligament avulsion fractures.Scientific reports · 2026Article
- Should We Recommend Vitamin K2 Supplement to Prevent Coronary Artery Calcification for Patients Receiving Statins and/or Warfarin?Cardiovascular drugs and therapy · 2025Review
- The Genetic Polymorphisms of CYP2C9 and VKORC1 in the Saudi Population and Their Impact on Anticoagulant Management.Medicina (Kaunas, Lithuania) · 2025Article
- Bio-Functional Nanomaterials for Enhanced Lung Cancer Therapy: The Synergistic Roles of Vitamins D and K.Journal of functional biomaterials · 2025Review
- Effect of Warfarin on Lifespan and Oxidative Stress Tolerance ofInternational journal of molecular sciences · 2025Article
- Vitamin E (α-Tocopherol): Emerging Clinical Role and Adverse Risks of Supplementation in Adults.Cureus · 2025Review
- Observational
- The Effect of Spinach (Journal of blood medicine · 2025Article
- Naoxintong Is Involved in the Coagulation Regulation of Warfarin Through the MAPK Pathway.Pharmacogenomics and personalized medicine · 2025Article
- Harnessing the Human Microbiome for Innovative Drug Delivery Systems: Exploring Pharmacomicrobiomics and Targeted Therapies.Current pharmaceutical design · 2025Review
- Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review.Cureus · 2024Review
- Interaction of the lysozyme with anticoagulant drug warfarin: Spectroscopic and computational analyses.Heliyon · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Vitamin K epoxide reductase (VKOR), an endoplasmic reticulum membrane protein, is the key enzyme for vitamin K-dependent carboxylation, a posttranslational modification that is essential for the biological functions of coagulation factors. VKOR is the target of the most widely prescribed oral anticoagulant, warfarin. However, the topological structure of VKOR and the mechanism of warfarin's inhibition of VKOR remain elusive. Additionally, it is not clear why warfarin-resistant VKOR mutations identified in patients significantly decrease warfarin's binding affinity, but have only a minor effect on vitamin K binding. Here, we used immunofluorescence confocal imaging of VKOR in live mammalian cells and PEGylation of VKOR's endogenous cytoplasmic-accessible cysteines in intact microsomes to probe the membrane topology of human VKOR. Our results show that the disputed loop sequence between the first and second transmembrane (TM) domain of VKOR is located in the cytoplasm, supporting a 3-TM topological structure of human VKOR. Using molecular dynamics (MD) simulations, a T-shaped stacking interaction between warfarin and tyrosine residue 139, within the proposed TY
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.